

WE CLAIM:

1. An aqueous nasal spray composition comprising a therapeutically effective amount of a medicament and an aqueous carrier comprising from 0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone and mixtures thereof.
2. An aqueous nasal spray composition comprising of an effective amount of a medicament in an aqueous carrier comprising:
 - 0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone and mixtures thereof;
 - 0.00 to 15.00% by weight/volume of polyethylene glycol;
 - 0.00 to 10.00% by weight/volume of a moisturizing agent or mixtures of moisturizing agents;
 - 0.00 to 10.00% by weight/volume of an antioxidant;
 - 0.001 to 0.10% by weight/volume of an antimicrobial preservative;
 - ; 0.00 to 5.00% by weight/volume of an aromatic alcohol;
 - a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0 and
 - QS water.
3. The aqueous nasal spray composition of claim 2 comprising of an effective amount of a medicament in an aqueous carrier comprising:

- 0.50 to 2.5% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone and mixtures thereof;
- 5 0.5 to 10.00% by weight/volume of polyethylene glycol;
- 1.00 to 4.00% by weight/volume of a moisturizing agent;
- 10 0.01 to 0.05% by weight/volume of an antioxidant;
- 0.02 to 0.025% by weight/volume of an antimicrobial preservative;
- 0.20 to 3.00% by weight/volume of an aromatic alcohol;
- 15 a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0 and
- QS water.
- 20
4. The aqueous nasal spray composition of claim 2 comprising of an effective amount of a medicament in an aqueous carrier comprising:
- 25 1.00 to 1.50% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone and mixtures thereof;
- 2.5 to 5.00% by weight/volume of polyethylene glycol;
- 30 1.50 to 3.50% by weight/volume of a moisturizing agent or mixtures of moisturizing agents;
- 0.015 to 0.030% by weight/volume of an antioxidant;

0.02 to 0.025% by weight/volume of an
antimicrobial preservative;

0.25 to 1.00% by weight/volume of an aromatic
alcohol;

5 a sufficient amount of a pharmaceutically
acceptable buffer to maintain the pH of the
composition within the range of about 4.0 to
8.0 and

QS water.

10

5. The aqueous nasal spray composition of claim 2
wherein the moisturizing agent is propylene glycol; the
antioxidant is disodium EDTA; the antimicrobial preservative
is benzalkonium chloride; and the aromatic alcohol is benzyl
15 alcohol; and the buffer is a phosphate buffer.

6. The aqueous nasal spray composition of claim 5
wherein the medicament is selected from the group consisting
of chlorpheniramine maleate, oxymetazoline hydrochloride
20 and mixtures thereof.

7. The aqueous nasal spray composition of claim 6
wherein the medicament is oxymetazoline hydrochloride.

25 8. The aqueous nasal spray composition of claim 6
wherein the medicament is chlorpheniramine maleate.

9. The aqueous nasal spray composition of claim 2
which comprises:

30

INGREDIENTS

% Wt/Vol

Water

QS

Disodium EDTA

0.0200

Sodium Phosphate Dibasic

0.0975

Sodium Phosphate Monobasic

0.5525

09947344.000001

	PVP K-90	0.2500
	PVP K-30	1.0000
	PEG 1450	2.5000
	Benzyl Alcohol	0.2500
5	Benzalkonium Chloride (17% solution)	0.0200
	Chlorpheniramine Maleate	0.5000
	Oxymetazoline Hydrochloride	0.0500

10. The aqueous nasal spray composition of claim 2

10 which comprises:

	<u>INGREDIENTS</u>	<u>% Wt/Vol</u>
	Water	QS
	Disodium EDTA	0.0200
15	Sodium Phosphate Dibasic	0.0975
	Sodium Phosphate Monobasic	0.5525
	PVP K-90	0.2500
	PVP K-30	1.0000
	PEG 1450	2.5000
20	Benzyl Alcohol	0.2500
	Benzalkonium Chloride (17% solution)	0.0200
	Oxymetazoline Hydrochloride	0.0500
	:	

11. The aqueous nasal spray compositions of claim 2

25 which comprises:

	<u>INGREDIENTS</u>	<u>% Wt/Vol</u>
	Water	QS
	Disodium EDTA	0.0200
30	Sodium Phosphate Dibasic	0.0975
	Sodium Phosphate Monobasic	0.5525
	PVP K-30	3.0000
	PEG 600	5.0000
	Benzyl Alcohol	0.2500

Benzalkonium Chloride (17% solution)	0.0200
Oxymetazoline Hydrochloride	0.0500
Chlorpheniramine Maleate	0.5000

- 5 12. The aqueous nasal spray composition of claim 2
which comprises:

	<u>INGREDIENTS</u>	<u>% Wt/Vol</u>
	Water	QS
10	Disodium EDTA	0.0200
	Sodium Phosphate Dibasic	0.0975
	Sodium Phosphate Monobasic	0.5525
	PVP K-30	3.0000
	PEG 1450	5.0000
15	Benzyl Alcohol	0.2500
	Benzalkonium Chloride (17% solution)	0.0200
	Oxymetazoline Hydrochloride	0.0500
	Chlorpheniramine Maleate	0.5000

- 20 13. The aqueous nasal spray composition of claim 2
which comprises:

	<u>INGREDIENTS</u>	<u>% Wt/Vol</u>
	Water	QS
25	Disodium EDTA	0.0200
	Sodium Phosphate Dibasic	0.0975
	Sodium Phosphate Monobasic	0.5525
	PVP K-90	0.1000
	PVP K-30	3.0000
30	PEG 1450	2.5000
	Propylene glycol	0.2500
	Benzalkonium Chloride (17% solution)	0.1471
	Oxymetazoline Hydrochloride	0.0500

0940734-032341
19920-1870460

14. The aqueous nasal spray composition of claim 2 which comprises:

	<u>INGREDIENTS</u>	<u>% Wt/Vol</u>
5	Water	QS
	Disodium EDTA	0.0200
	Sodium Phosphate Dibasic	0.0975
	Sodium Phosphate Monobasic	0.5525
10	PVP K-90	0.1000
	PVP K-30	3.0000
	PEG 1450	5.0000
	Propylene Glycol	2.0000
	Glycerin	0.1000
15	Benzalkonium Chloride (17% solution)	0.1471
	Oxymetazoline Hydrochloride	0.0500

03940784-000001